Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.

Hdl Handle:
http://hdl.handle.net/10147/208012
Title:
Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.
Authors:
Bolton, S; Cleary, B; Walsh, J; Dempsey, E; Turner, M J
Affiliation:
UCD School of Medicine and Medical Science, Coombe Women's Hospital, Dublin 8,, Ireland.
Citation:
Eur J Pediatr. 2009 Feb;168(2):203-6. Epub 2008 May 7.
Journal:
European journal of pediatrics
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/208012
DOI:
10.1007/s00431-008-0737-7
PubMed ID:
18461356
Abstract:
This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy. All women with polycystic ovary syndrome (PCOS) treated with metformin in the first trimester and who delivered a baby weighing 500 g or more between 2003 and 2005 were studied. Subjects were matched for age and parity with randomly selected controls. The perinatal outcomes studied were: growth parameters, gestational age, congenital defects, hypoglycaemia and neonatal unit admission. Sixty-six pregnancies were compared with 66 controls; all had singleton deliveries. There was no difference in mean birth weight between the metformin and the control groups (p=0.84). The percentage of small (<10th centile) and large (>90th centile) for gestational age babies was lower in the metformin group. In the metformin group, there were no major congenital malformations and 24% of the babies were admitted to the neonatal intensive care unit (NICU) compared with 27% of the babies in the control group (non-significant). Neonatal hypoglycaemia was less common in the metformin group (18.5% vs. 24.5%) and fewer babies required intravenous glucose therapy (6.3% vs. 12%). We found no evidence that the continuation of metformin in the first trimester of pregnancy was associated with an adverse foetal outcome.
Language:
eng
MeSH:
Adult; Birth Weight/drug effects; Female; Humans; Hypoglycemic Agents/*administration & dosage/therapeutic use; Infant, Newborn; Insulin Resistance; Metformin/*adverse effects/therapeutic use; *Ovulation Induction; Polycystic Ovary Syndrome/*drug therapy; Pregnancy; Pregnancy Complications/*drug therapy; Pregnancy Outcome; Pregnancy Trimester, First; Reference Values; Treatment Outcome
ISSN:
1432-1076 (Electronic); 0340-6199 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorBolton, Sen_GB
dc.contributor.authorCleary, Ben_GB
dc.contributor.authorWalsh, Jen_GB
dc.contributor.authorDempsey, Een_GB
dc.contributor.authorTurner, M Jen_GB
dc.date.accessioned2012-02-01T10:57:39Z-
dc.date.available2012-02-01T10:57:39Z-
dc.date.issued2012-02-01T10:57:39Z-
dc.identifier.citationEur J Pediatr. 2009 Feb;168(2):203-6. Epub 2008 May 7.en_GB
dc.identifier.issn1432-1076 (Electronic)en_GB
dc.identifier.issn0340-6199 (Linking)en_GB
dc.identifier.pmid18461356en_GB
dc.identifier.doi10.1007/s00431-008-0737-7en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208012-
dc.description.abstractThis study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy. All women with polycystic ovary syndrome (PCOS) treated with metformin in the first trimester and who delivered a baby weighing 500 g or more between 2003 and 2005 were studied. Subjects were matched for age and parity with randomly selected controls. The perinatal outcomes studied were: growth parameters, gestational age, congenital defects, hypoglycaemia and neonatal unit admission. Sixty-six pregnancies were compared with 66 controls; all had singleton deliveries. There was no difference in mean birth weight between the metformin and the control groups (p=0.84). The percentage of small (<10th centile) and large (>90th centile) for gestational age babies was lower in the metformin group. In the metformin group, there were no major congenital malformations and 24% of the babies were admitted to the neonatal intensive care unit (NICU) compared with 27% of the babies in the control group (non-significant). Neonatal hypoglycaemia was less common in the metformin group (18.5% vs. 24.5%) and fewer babies required intravenous glucose therapy (6.3% vs. 12%). We found no evidence that the continuation of metformin in the first trimester of pregnancy was associated with an adverse foetal outcome.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshBirth Weight/drug effectsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHypoglycemic Agents/*administration & dosage/therapeutic useen_GB
dc.subject.meshInfant, Newbornen_GB
dc.subject.meshInsulin Resistanceen_GB
dc.subject.meshMetformin/*adverse effects/therapeutic useen_GB
dc.subject.mesh*Ovulation Inductionen_GB
dc.subject.meshPolycystic Ovary Syndrome/*drug therapyen_GB
dc.subject.meshPregnancyen_GB
dc.subject.meshPregnancy Complications/*drug therapyen_GB
dc.subject.meshPregnancy Outcomeen_GB
dc.subject.meshPregnancy Trimester, Firsten_GB
dc.subject.meshReference Valuesen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleContinuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.en_GB
dc.contributor.departmentUCD School of Medicine and Medical Science, Coombe Women's Hospital, Dublin 8,, Ireland.en_GB
dc.identifier.journalEuropean journal of pediatricsen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.